REFERENCES
- Burke L B, Jolson H M, Goetsch R A, Ahronheirn J C. Geriatric drug use and adverse drug event reporting in 1990: A descriptive analysis of two national data bases. Annual Review of Gerontology and Geriatrics, 1992: Focus on Medications and the Elderly, J Rowe, J C Ahronheirn. Volume 12, Springer, New York 1993; 1–27
- US Food and Drug Administration, 1998
- Piercey M F, Hoffman W E, Smith M W, et al. Inhibition of dopamine neuron firing by pramipexole, a dopamine D3 receptor-preferring agonist: Comparison to other dopamine receptor agonists. Eur Neuropsychopharmacol 1996; 312: 35–44
- Lagos P, Scorza C, Monti J M, et al. Effects of the D3 preferring dopamine agonist pramipexole on sleep and waking, locomotor activity and striatal dopamine release in rats. Eur Neuropsychopharmacol 1998; 8: 113–120
- Gottwald M D, Bainbridge J L, Dowling G A, et al. New pharmacotherapy for Parkinson's disease. Ann Pharmacother 1997; 32: 1205–1216
- Mirapex® product information packet. Pharmacia & Upjohn Company, Kalamazoo, Michigan July 1997